Comparison Overview

Novo Nordisk

VS

PT Kalbe Farma, Tbk

Novo Nordisk

Novo Alle, Bagsværd, undefined, 2880, DK
Last Update: 2025-12-10
Between 800 and 849

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 64,615
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

PT Kalbe Farma, Tbk

KALBE Building, Jl. Letjen Suprapto Kav 4, Jakarta, DKI Jakarta, ID, 10510
Last Update: 2025-12-09
Between 750 and 799

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,334
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Novo Nordisk
100%
Compliance Rate
0/4 Standards Verified
PT Kalbe Farma, Tbk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novo Nordisk in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for PT Kalbe Farma, Tbk in 2025.

Incident History — Novo Nordisk (X = Date, Y = Severity)

Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Incident History — PT Kalbe Farma, Tbk (X = Date, Y = Severity)

PT Kalbe Farma, Tbk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
Incidents

No Incident

https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
Incidents

No Incident

FAQ

Novo Nordisk company demonstrates a stronger AI Cybersecurity Score compared to PT Kalbe Farma, Tbk company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, PT Kalbe Farma, Tbk company has disclosed a higher number of cyber incidents compared to Novo Nordisk company.

In the current year, PT Kalbe Farma, Tbk company and Novo Nordisk company have not reported any cyber incidents.

Neither PT Kalbe Farma, Tbk company nor Novo Nordisk company has reported experiencing a ransomware attack publicly.

Neither PT Kalbe Farma, Tbk company nor Novo Nordisk company has reported experiencing a data breach publicly.

Neither PT Kalbe Farma, Tbk company nor Novo Nordisk company has reported experiencing targeted cyberattacks publicly.

Neither Novo Nordisk company nor PT Kalbe Farma, Tbk company has reported experiencing or disclosing vulnerabilities publicly.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds any compliance certifications.

Neither company holds any compliance certifications.

PT Kalbe Farma, Tbk company has more subsidiaries worldwide compared to Novo Nordisk company.

Novo Nordisk company employs more people globally than PT Kalbe Farma, Tbk company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds SOC 2 Type 1 certification.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds SOC 2 Type 2 certification.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds ISO 27001 certification.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds PCI DSS certification.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds HIPAA certification.

Neither Novo Nordisk nor PT Kalbe Farma, Tbk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description

Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.

Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description

The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N